as is evident from the swift pursuit of RNA vaccine candidates for the global SARS-CoV-2 pandemic. Both conventional and self-amplifying RNAs have shown protective immunization in preclinical studies against multiple infectious diseases including influenza, RSV, Rabies, Ebola, and HIV-1. Self-amplif...
“As our Phase 1 data set grows, the potential advantages of the immune response induced by our samRNA vaccine candidates compared to currently approved COVID-19 vaccines is becoming increasingly clear. The ability of our candi...
RNA-based vaccines are an attractive candidate for this role: they are safe, are produced cell free, and can be rapidly generated in response to pathogen emergence. Two RNA vaccine platforms are available: synthetic mRNA molecules encoding only the antigen of interest and self-amplifying RNA (sa...
This is corroborated by the findings of Pepini et al., who used microarrays to measure changes in local gene expression following intramuscular injection with a self-amplifying RNA vaccine.1 They identified the upregulation of several chemokines, including Ccl2, Ccl7, Cxcl9, Cxcl10, and Cxcl1...
Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and...
Self-amplifying messenger ribonucleic acid (saRNA) provides extended expression of genes of interest by encoding an alphavirus-derived RNA replicase and thus is 2–3 times larger than conventional messenger RNA. However, quality assessment of long RNA tr
(self-amplifying RNA formulated in lipid nanoparticles; samRNA), an individualized neoantigen cancer vaccine, in combination with i.v. nivolumab and s.c. ipilimumab, in patients with metastatic NSCLC, MSS-CRC, GEA and metastatic urothelial cancer. The phase 1 portion of the study was designed ...
found 1 μg and 10 μg doses of an investigational lipid encapsulated SARS-CoV-2 sa-RNA vaccine induced neutralizing and anti-spike-IgG antibodies although there was only a modest correlation between the two measures31,32,33,34. The study has recently completed and some of the ...
vaccine design2. Although early studies focused on the use of DNA instead of RNA, the effectiveness of DNA-based vaccines was lower than RNA-based vaccines3. Interestingly, RNA molecules are more unstable but they are more efficient invitro and invivo, especially when used together with ...
Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design J. Immunol., 198 (2017), pp. 4012-4024 CrossrefView in ScopusGoogle Scholar 54 L. Lambricht, K. Vanvarenberg, A. De Beuckelaer, L. Van Hoecke, J. Grooten, B. Ucakar, ...